Share this article
Share this article
ResearchAndMarkets.com's offering.
The U.S. pharmaceutical analytical testing outsourcing market size is expected to reach USD 5.55 billion by 2027. It is expected to expand at a CAGR of 8.3% from 2020 to 2027.
The market is mainly driven by an increasing number of clinical trial registrations, innovations in the medical industry, and the entry of new players in the market. Moreover, increasing R&D investment, growing demand for biopharmaceutical products, and rising focus on regulation, safety, and quality are some of the major factors responsible for the growth of the market.
The increasing development of the pharmaceutical analytical testing services market has fascinated many new players in the industry, leading to growing competition for well established, standalone service providers. The rapid increase in the manufacturing of medications to meet the rising demand for efficient healthcare in the U.S. is projected to be one of the major factors driving the demand for pharmaceutical analytical testing outsourcing services. For example, the increasing prevalence of preventable illness and the suboptimal use of healthcare resources have led to rising demand for efficient healthcare in the U.S.